Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients
Hematological Oncology · 2025
DOI: 10.1002/hon.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Tatsuzo Mishina und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Chiba University Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: POEMS Syndrome, Osteolysis. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
POEMS syndrome is a multisystemic disease associated with monoclonal plasma cell disorders. Although the presence of bone lesions is included in the diagnostic criteria, their precise manifestations remain unknown. Here, we retrospectively analyzed the bone lesions in patients with POEMS syndrome and evaluated their clinical features. Clinical data and bone lesion information by computed tomography (CT) imaging were obtained from the 114 patients with POEMS syndrome. Regardless of the presence of sclerotic bone lesions, patients were divided into two groups according to the presence (lytic group: n = 17, 14.9%) or absence (non‐lytic group: n = 97, 85.1%) of osteolytic lesions. In the lytic group, several patients were histologically diagnosed with plasmacytoma. In the evaluation by CT imaging, osteolytic lesions had a higher response rate than sclerotic lesions (75.0% vs. 42.2%, p = 0.079). Nevertheless, patients in lytic group showed earlier clinical progression than patients in non‐lytic group (2‐year progression‐free survival, 66.7% vs. 90.2%, p = 0.069). The presence of innumerable bone lesions was an independent poor prognostic factor in multivariate analysis, regardless of the presence of osteolytic lesions (hazard ratio, 3.4; 95% confidence interval 1.1–10.9; p = 0.040). Osteolytic and innumerable bone lesions are potential prognostic factors. Further studies involving histopathological evaluations of bone lesions are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Chiba University Hospital, Chiba, Japan.
- Division of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
- Department of Hematology, International University of Health and Welfare, Narita, Japan.
- Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan.
ORCID-Profile: Tatsuzo Mishina, Shokichi Tsukamoto, Chiaki Nakaseko
Zitieren
APA
Mishina, T., Ohwada, C., Suichi, T., Matsui, S., Ishii, A., Takaishi, K., Oshima-Hasegawa, N., Tsukamoto, S., Takeda, Y., Misawa, S., Mimura, N., Kuwabara, S., Nakaseko, C., & Sakaida, E. (2025). Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients. Hematological Oncology. https://doi.org/10.1002/hon.70037
Vancouver
Mishina T, Ohwada C, Suichi T, Matsui S, Ishii A, Takaishi K, et al. Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients. Hematological Oncology. 2025. doi:10.1002/hon.70037
BibTeX
@article{Mishina2025,
author = {Mishina, Tatsuzo and Ohwada, Chikako and Suichi, Tomoki and Matsui, Shinichiro and Ishii, Arata and Takaishi, Koji and Oshima-Hasegawa, Nagisa and Tsukamoto, Shokichi and Takeda, Yusuke and Misawa, Sonoko and Mimura, Naoya and Kuwabara, Satoshi and Nakaseko, Chiaki and Sakaida, Emiko},
title = {Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70037}
}
EUVIMED